Published online before print December 21, 2007

This Article Full Text (Rapid PDF) All Versions of this Article: ajpath.2008.070065v1 172/1/225    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Peng, Y. Articles by Lee, P. Search for Related Content PubMed PubMed Citation Articles by Peng, Y. Articles by Lee, P.

Copyright © 2008 American Society for Investigative Pathology
American Journal of Pathology, doi:10.2353/ajpath.2008.070065

Accepted for publication October 4, 2007.

Article

Stimulation of Prostate Cancer Cellular Proliferation and Invasion by the Androgen Receptor Co-Activator ARA70

Yi Peng^*, Caihong X. Li^*, Fei Chen^*, Zhengxin Wang, Martin Ligr^*, Jonathan Melamed^*, Jianjun Wei^*, William Gerald, Michele Pagano^*, Michael J. Garabedian, and Peng Lee^*¶@

From the Departments of Pathology,* and Microbiology and Urology, New York University School of Medicine, New York, New York; the New York Harbor Healthcare System,^¶ New York, New York; the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; and the Department of Cancer Biology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas

^@ To whom correspondence should be addressed. E-mail: peng.lee{at}med.nyu.edu.

	Abstract

ARA70 was first identified as a gene fused to the ret oncogene in thyroid carcinoma and subsequently as a co-activator for androgen receptor (AR). Two isoforms of ARA70 have been identified: a 70-kDa version called ARA70 and an internally spliced 35-kDa variant termed ARA70. We have previously reported that ARA70 expression is reduced in prostate cancer, and its overexpression inhibits proliferation of LNCaP prostate cancer cells. However, the function of the ARA70 isoform in prostate cancer is not understood. In this report we examined the effects of ARA70 on AR transcriptional regulation as well as prostate cancer cellular proliferation and invasion. Although both ARA70 and ARA70 functioned as transcriptional co-activators of AR in cell-based reporter assays, ARA70 overexpression, in contrast to ARA70, promoted prostate cancer cellular proliferation and invasion through Matrigel. Interestingly, genome-wide expression profiling of cells expressing ARA70 revealed an increase in the expression of genes involved in the control of cell division and adhesion, compatible with a role for ARA70 in proliferation and invasion. Consistent with its function in promoting cell growth and invasion, ARA70 expression was increased in prostate cancer. Our findings implicate ARA70 as a regulator of tumor cell growth and metastasis by affecting gene expression.